Tevogen Bio's First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned
Current ownership breakdown: Insiders 79%; Independent Board Members 1%; Lead Investor 7%; SPAC Sponsor 6%; Others 8%.
Assets believed to be valued in the billions. (Not reflected on Tevogen's balance sheet as internally developed intangible assets are generally not permitted to be capitalized as per US GAAP).
Additional business updates to follow in coming days.
WARREN, N.J., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio ('Tevogen Bio Holdings Inc.' or 'Company') (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, aims to set new efficiency standards in the industry, to prove that innovation and cost-effectiveness can coexist. Built with the rising cost of drug development in mind, Tevogen's model aligns with current drug price reform efforts while challenging traditional biotech financing norms to ensure long-term sustainability.
'In today's rapidly changing biotech landscape, efficiency is not just a competitive advantage, it's a necessity. Rising drug costs and shifting market dynamics demand a new approach, and Tevogen Bio is proving that groundbreaking innovation may be achieved without excessive spending,' commented Ryan Saadi, MD, MPH, Founder and CEO of Tevogen Bio.
About Tevogen Bio
Tevogen Bio is a clinical-stage specialty immunotherapy company harnessing one of nature's most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies to treat infectious disease and cancers, aiming to address the significant unmet needs of large patient populations. Tevogen Bio leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen Bio has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence.
Tevogen Bio is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen Bio's leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.
Forward Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: expectations regarding the healthcare and biopharmaceutical industries; Tevogen's development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer; Tevogen's plans to expand its efforts in artificial intelligence; Tevogen's ability to develop additional product candidates; Tevogen's use of funds from the grant; and the potential receipt of additional future grants. Forward-looking statements can sometimes be identified by words such as 'may,' 'could,' 'would,' 'expect,' 'anticipate,' 'possible,' 'potential,' 'goal,' 'opportunity,' 'project,' 'believe,' 'future,' and similar words and expressions or their opposites. These statements are based on management's expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company's control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the effect of the recent business combination with Semper Paratus Acquisition Corporation (the 'Business Combination') on Tevogen's business relationships, operating results, and business generally; the outcome of any legal proceedings that may be instituted against Tevogen; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; costs related to the Business Combination and the failure to realize anticipated benefits of the Business Combination; the failure to achieve Tevogen's commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; the ability to develop, license or acquire new therapeutics; that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk of regulatory lawsuits or proceedings relating to Tevogen's business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen's limited operating history; and those factors discussed or incorporated by reference in Tevogen's Annual Report on Form 10-K and subsequent filings with the SEC.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Contacts
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
Alphabet (NASDAQ:GOOGL) Posts Better-Than-Expected Sales In Q2
Online advertising giant Alphabet (NASDAQ:GOOGL) reported Q2 CY2025 results beating Wall Street's revenue expectations , with sales up 13.8% year on year to $96.43 billion. Its GAAP profit of $2.31 per share was 5.7% above analysts' consensus estimates. Is now the time to buy Alphabet? Find out in our full research report. Alphabet (GOOGL) Q2 CY2025 Highlights: Revenue: $96.43 billion vs analyst estimates of $93.98 billion (2.6% beat) Operating Profit (GAAP): $31.27 billion vs analyst estimates of $31.09 billion (0.6% beat) EPS (GAAP): $2.31 vs analyst estimates of $2.19 (5.7% beat) Google Search Revenue: $0.02 vs analyst estimates of $52.92 billion (2.4% beat) Google Cloud Revenue: $0.04 vs analyst estimates of $13.12 billion (3.8% beat) YouTube Revenue: $9.80 billion vs analyst estimates of $9.58 billion (2.3% beat) Google Services Operating Profit: $0.01 vs analyst estimates of $32.77 billion (small beat) Google Cloud Operating Profit: $0.26 vs analyst estimates of $2.24 billion (26.2% beat) Operating Margin: 32.4%, in line with the same quarter last year "With this strong and growing demand for our Cloud products and services, we are increasing our investment in capital expenditures in 2025 to approximately $85 billion and are excited by the opportunity ahead" - CEO Free Cash Flow Margin: 5.5%, down from 15.9% in the same quarter last year Market Capitalization: $2.33 trillion Sundar Pichai, CEO, said: "We had a standout quarter, with robust growth across the company. We are leading at the frontier of AI and shipping at an incredible pace. AI is positively impacting every part of the business, driving strong momentum. Search delivered double-digit revenue growth, and our new features, like AI Overviews and AI Mode, are performing well. We continue to see strong performance in YouTube as well as subscriptions offerings. And Cloud had strong growth in revenues, backlog and profitability. Its annual revenue run-rate is now more than $50 billion. With this strong and growing demand for our Cloud products and services, we are increasing our investment in capital expenditures in 2025 to approximately $85 billion and are excited by the opportunity ahead.' Revenue Growth Alphabet shows that fast growth and massive scale can coexist despite conventional wisdom. The company's revenue base of $166 billion five years ago has more than doubled to $371.4 billion in the last year, translating into an incredible 17.5% annualized growth rate. Alphabet's growth over the same period was also higher than its big tech peers, Amazon (16.6%), Microsoft (14.4%), and Apple (8%). Comparing the four is relevant because investors often pit them against each other to derive their valuations. With these benchmarks in mind, we think Alphabet is cheap. We at StockStory emphasize long-term growth, but for big tech companies, a half-decade historical view may miss emerging trends in AI. Alphabet's annualized revenue growth of 13.3% over the last two years is below its five-year trend, but we still think the results suggest healthy demand. This quarter, Alphabet reported year-on-year revenue growth of 13.8%, and its $96.43 billion of revenue exceeded Wall Street's estimates by 2.6%. Looking ahead, sell-side This projection is still healthy and illustrates the market sees some success for its newer products. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Google Search: Alphabet's Bread-and-Butter The most topical question surrounding Alphabet today is: 'Will new Generative-AI products like ChatGPT and Meta AI disrupt Google Search and its 80%+ market share?'. Although OpenAI (creator of ChatGPT) doesn't disclose its financials, we can gain further insight by comparing Google Search to Meta and Microsoft's Bing. Meta essentially has a monopoly in social media advertising and is creeping into search with Meta AI, which is powered by its Llama large language model, while Bing is the distant number two search engine that benefits from its integration with ChatGPT. Starting with Alphabet, Google Search is by far the most considerable portion of its revenue at 56.1%, and it grew at a 16.3% annualized rate over the last five years, slower than total revenue. The previous two years also saw deceleration as it grew by 12.3% annually, though this isn't concerning since it's still expanding quickly. On the other hand, its two-year result was lower than Meta's 21.8%, showing digital advertising dollars could be flowing to Meta because of its improved AI algorithms and targeting capabilities. Alphabet bulls would argue this trend could reverse because the return on investment from keyword-driven advertising is more tangible, but that hasn't been the case lately. Quarterly performance is particularly relevant for Alphabet because it captures the growth of AI and signals whether investors are overestimating its competitive impact. Bulls can rejoice as Google Search revenue exceeded expectations in Q2, outperforming Wall Street Consensus by 2.4%. The segment recorded a hearty year-on-year increase of 11.7%. While this was slower than Bing's 23%, it's important to consider that Bing has a much smaller revenue base and doesn't pose a significant threat yet. Still, Alphabet must continue topping Wall Street's Google Search projections and performing well in other segments like Google Cloud Platform and YouTube to win the debate. Key Takeaways from Alphabet's Q2 Results It was encouraging to see Alphabet narrowly top analysts' revenue expectations this quarter, as Google Cloud Platform, Google Search, and YouTube all beat. We were also glad its operating profit in the Services and Cloud segments outperformed Wall Street's estimates. On the other hand, management stated that "we are increasing our investment in capital expenditures in 2025 to approximately $85 billion...." Overall, we think this was a solid quarter with some key areas of upside, but the market could be concerned about deteriorating cash generation due to higher capex forecasts, and shares traded down 1.3% to $187.88 immediately after reporting. So should you invest in Alphabet right now? What happened in the latest quarter matters, but not as much as longer-term business quality and valuation, when deciding whether to invest in this stock. We cover that in our actionable full research report which you can read here, it's free. Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Business Wire
3 minutes ago
- Business Wire
DiaMedica Therapeutics Announces Closing of $30.1 Million Private Placement
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the closing of its previously announced $30.1 million private placement of common shares to accredited investors. The Company sold approximately 8.6 million common shares at a purchase price of $3.50 per share. After deducting estimated offering expenses, the Company received net proceeds of approximately $29.9 million. The Company reported cash, cash equivalents and short-term investments of $37.3 million as of March 31, 2025. On a pro forma basis, including the estimated $29.9 million in net proceeds from the private placement, the Company's cash, cash equivalents and short-term investments would have been $67.2 million as of such date. The securities sold in the private placement have not been registered under the U.S. Securities Act of 1933, as amended, or any state or other applicable jurisdiction's securities laws, and may not be offered or sold in the United States absent such registration or an applicable exemption therefrom. The Company has agreed to file a registration statement with the U.S. Securities and Exchange Commission registering the resale of the common shares issued in the private placement within ten (10) days following closing. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the Company's securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Required Canadian Related Party Transaction Disclosure Certain non-management related parties of DiaMedica has participated in the private placement, acquiring the aggregate amount of $16.8 million or 4,799,999 common shares. Accordingly, the private placement constitutes a "related party transaction" as such term is defined in Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (" MI 61-101") of the Canadian Securities Administrators. The private placement is exempt from the valuation and the minority shareholder approval requirements of MI 61-101 under the exemptions contained in section 5.5(a) and 5.7(1)(a), respectively, as neither the fair market value of the common shares nor the fair market value of the consideration paid for the common shares insofar as it involves the related parties is more than 25% of the Company's market capitalization. The private placement was unanimously approved by a special committee comprised of independent members of the Company's board of directors. As the material change report relating to the completion of the private placement will be filed on SEDAR+ less than 21 days before the completion of the private placement, there is a requirement under MI 61–101 to explain why the shorter period is reasonable or necessary in the circumstances. In DiaMedica's view, the shorter period is reasonable and necessary in the circumstances because the related parties and the Company wished to complete the private placement in a fashion that resulted in the invested funds being received directly by the Company in a timely manner such that the funds could be accessed immediately by the Company to advance its ongoing research and development activities. Required Canadian Early Warning Reporting Upon closing of the private placement, Thomas von Koch (the 'von Koch'), Brahegatan 10, Box 3676 Stockholm, Sweden, will acquire indirect ownership, through TomEnterprise Private AB, of an aggregate of 2,857,142 common shares (the 'von Koch Shares') of DiaMedica (the 'von Koch Acquisition'). The Company's head office is located at 301 Carlson Parkway, Suite 210, Minneapolis, Minnesota, 55305, U.S.A. Immediately prior to the completion of the von Koch Acquisition, von Koch had ownership of, and exercised control and direction over, an aggregate of 5,526,435 common shares of the Company representing approximately 12.8% of the issued and outstanding common shares of the Issuer on a non-diluted basis. Immediately following the completion of the von Koch Acquisition, von Koch will have ownership of, and exercise control and direction over, an aggregate of 8,383,577 common shares of the Company representing approximately 16.2% of the issued and outstanding common shares of the Company on a non-diluted basis. von Koch will pay aggregate cash consideration of US$10,000,000 (approximately C$13,600,000) for the von Koch Shares at a price of US$3.50 per common share (approximately C$4.77). The von Koch Shares are being acquired for investment purposes. von Koch may, from time to time, take such actions in respect of his holdings in securities of the Company as he may deem appropriate in light of the circumstances then existing, including the purchase of additional common shares or other securities of the Company or the disposition of all or a portion of his security holdings in the Company, subject in each case to applicable securities laws and the terms of such securities. Upon closing of the private placement, Trill AB ('Trill'), Sveavägen 17, 18th Floor, SE-111 57, Stockholm, Sweden, acquired ownership of an aggregate of 1,542,857 common shares (the 'Trill Shares') of the Company (the 'Trill Acquisition'). Immediately prior to the completion of the Trill Acquisition, Trill had ownership of, and exercised control and direction over, an aggregate of 5,221,608 common shares of the Company representing approximately 12.1% of the issued and outstanding common shares of the Company on a non-diluted basis. Immediately following the completion of the Trill Acquisition, Trill will have ownership of, and exercise control and direction over, an aggregate of 6,764,465 common shares of the Company representing approximately 13.1% of the issued and outstanding common shares of the Company on a non-diluted basis. Trill will pay aggregate cash consideration of US$5,000,000 (approximately C$7,400,000) for the Trill Shares at a price of US$3.50 per common share (approximately C$4.77). The Trill Shares are being acquired for investment purposes. Trill may, from time to time, take such actions in respect of its holdings in securities of the Company as it may deem appropriate in light of the circumstances then existing, including the purchase of additional common shares or other securities of the Company or the disposition of all or a portion of its security holdings in the Company, subject in each case to applicable securities laws and the terms of such securities. Upon closing of the private placement, NFS/FMTC Roth IRA FBO Richard Jacinto II ('Jacinto'), c/o Fidelity Investments, 100 Crosby Parkway, Mail zone KC1H, Covington, KY 41015, will acquire ownership of an aggregate of 400,000 common shares (the 'Jacinto Shares') of the Company (the 'Jacinto Acquisition'). Immediately prior to the completion of the Jacinto Acquisition, Jacinto had ownership of, and exercised control and direction over, an aggregate of 4,558,823 common shares of the Company representing approximately 10.6% of the issued and outstanding common shares of the Company on a non-diluted basis. Immediately following the completion of the Jacinto Acquisition, Jacinto will have ownership of, and exercise control and direction over, an aggregate of 4,958,823 common shares of the Company representing approximately 9.6% of the issued and outstanding common shares of the Company on a non-diluted basis. Jacinto paid aggregate cash consideration of US$1,400,000 (approximately C$1,900,000) for the Jacinto Shares at a price of US$3.50 per common share (approximately C$4.77). The Jacinto Shares are being acquired for investment purposes. Jacinto may, from time to time, take such actions in respect of its holdings in securities of the Company as it may deem appropriate in light of the circumstances then existing, including the purchase of additional common shares or other securities of the Company or the disposition of all or a portion of its security holdings in the Company, subject in each case to applicable securities laws and the terms of such securities. Pursuant to National Instrument 62-103 - The Early Warning System and Related Take-Over Bid and Insider Reporting Issues, following the closing of the private placement, each of von Koch, Trill and Jacinto will file an early warning report in respect of the von Koch Acquisition, Trill Acquisition and Jacinto Acquisition, respectively, with the applicable Canadian securities regulators, copies of which will be available under the Company's profile at Following closing of the private placement, a copy of the early warning report relating to the von Koch Acquisition can be obtained by contacting von Koch at +46706034564, Per Colleen, CEO TomEqt Private AB. A copy of the early warning report relating to the Trill Acquisition can be obtained by contacting Trill at Sveavägen 17, 18th Floor, SE-111 57, Stockholm, Sweden. A copy of the early warning report relating to the Jacinto Acquisition can be obtained by contacting Jacinto at 301 Carlson Parkway, Suite 210, Minneapolis, MN 55305. The Canadian dollar values referred to above were determined using the Bank of Canada daily exchange rate on July 22, 2025. About DM199 DM199 is a recombinant (synthetic) form of human tissue kallikrein-1 (KLK1). KLK1 is a serine protease (protein) that plays an important role in the regulation of diverse physiological processes including blood flow, inflammation, fibrosis, oxidative stress and neurogenesis via a molecular mechanism that increases production of nitric oxide and prostaglandin. KLK1 deficiency may play a role in multiple vascular and fibrotic diseases such as stroke, chronic kidney disease, retinopathy, vascular dementia, and resistant hypertension where current treatment options are limited or ineffective. DiaMedica is the first company to have developed and clinically studied a recombinant form of the KLK1 protein. The KLK1 protein, produced from the pancreas of pigs and human urine, has been used to treat patients in Japan, China and South Korea for decades. DM199 is currently being studied in patients with acute ischemic stroke (AIS). In September 2021, the FDA granted Fast Track Designation to DM199 for the treatment of AIS. About DiaMedica Therapeutics Inc. DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on preeclampsia, fetal growth restriction and acute ischemic stroke. DiaMedica's lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information visit the Company's website at
Business Wire
3 minutes ago
- Business Wire
Priority Technology Holdings, Inc. To Announce Second Quarter 2025 Financial Results on August 7, 2025
ALPHARETTA, Ga.--(BUSINESS WIRE)--Priority Technology Holdings, Inc. (NASDAQ: PRTH) ('Priority' or the 'Company'), the payments and banking solution that streamlines collecting, storing, lending and sending money to unlock revenue opportunities, today announced that it will release its second quarter 2025 financial results on Thursday, August 7, 2025, before markets open. The Company will host a conference call and webcast to discuss its financial and operating results at 10:00 AM ET the same day. A question-and-answer session will follow. Second Quarter 2025 Conference Call Thursday, August 7, 2025 10:00 AM Eastern Time Phone: US/Canada: 833-636-1319 or International: 412-902-4286 Internet webcast link and accompanying slide presentation can be accessed at and will also be posted in the 'Investor Relations' section of the Company's website at An audio replay of the call will be available shortly after the conference call until Thursday, August 21, 2025, at 11:59 PM ET. To listen to the audio replay, dial 844-512-2921 or 412-317-6671 and enter access ID number 10200777. Alternatively, you may access the webcast replay in the 'Investor Relations' section of the Company's website at About Priority Technology Holdings, Inc. Priority is the payments and banking solution that enables businesses to collect, store, lend and send funds through a unified commerce engine. Our platform combines payables, merchant services, and banking and treasury solutions so leaders can streamline financial operations efficiently — and our innovative industry experts help businesses navigate and build momentum on the path to growth. With the Priority Commerce Engine, leaders can accelerate cash flow, optimize working capital, reduce unnecessary costs, and unlock new revenue opportunities. To learn more about Priority (NASDAQ: PRTH), visit
